El Hafny B, Cano N, Piciotti M, Regina A, Scherrmann J M, Roux F
INSERM U26, Unité de Neuro-Pharmaco-Nutrition, Hôpital Fernand Widal,Paris, France.
Biochem Pharmacol. 1997 Jun 1;53(11):1735-42. doi: 10.1016/s0006-2952(97)00093-2.
Uptake and efflux of colchicine and vinblastine, whose effects are related to their high-affinity binding to tubulin, were studied in the immortalized rat brain microvessel endothelial cell line RBE4. At 10 nM extracellular drug concentration, uptake equilibrium was approached at 45 hr for colchicine, but at only 3.5 hr for vinblastine. After 1 hr preincubation with 200 nM colchicine or vinblastine, drug efflux fitted biexponential kinetics with an initial fast phase (half-life = 2.2 min and 9.6 min, respectively) and a later slow phase (half-life = 3.6 hr and 1.8 hr, respectively). After 6 hr preincubation with 200 nM colchicine, only the slow phase (half-life = 3.6 hr) could be observed. The colchicine and vinblastine uptake rate was increased by cyclosporin A, an inhibitor of the drug efflux pump P-glycoprotein, which is expressed at the blood-brain barrier. Whereas cyclosporin A decreased vinblastine efflux, its effect on colchicine efflux was apparent after only 13 hr washout and was associated with the re-uptake by cells of colchicine molecules. Differences in uptake kinetics of colchicine and vinblastine could be related to differences in their lipid solubility, and mainly in their binding affinities to tubulin. Differences in efflux kinetics could in addition be explained by the involvement of P-glycoprotein in the efflux of vinblastine, whereas efflux of colchicine was not influenced by this pump. Indeed, binding of colchicine to tubulin would imply that most intracellular colchicine may be inaccessible to P-glycoprotein. In the case of a cytotoxic drug such as colchicine, which is tightly bound to intracellular receptors, the role of P-glycoprotein within the blood-brain barrier would be more to protect the brain against entry of this drug than to detoxify the brain by its extraction.
秋水仙碱和长春碱的摄取与外排情况在永生化大鼠脑微血管内皮细胞系RBE4中进行了研究,它们的作用与其与微管蛋白的高亲和力结合有关。在细胞外药物浓度为10 nM时,秋水仙碱在45小时达到摄取平衡,而长春碱仅在3.5小时达到摄取平衡。用200 nM秋水仙碱或长春碱预孵育1小时后,药物外排符合双指数动力学,有一个初始快速阶段(半衰期分别为2.2分钟和9.6分钟)和一个后期缓慢阶段(半衰期分别为3.6小时和1.8小时)。用200 nM秋水仙碱预孵育6小时后,只能观察到缓慢阶段(半衰期 = 3.6小时)。药物外排泵P-糖蛋白在血脑屏障中表达,其抑制剂环孢素A可提高秋水仙碱和长春碱的摄取率。虽然环孢素A降低了长春碱的外排,但它对秋水仙碱外排的影响仅在洗脱13小时后才明显,且与秋水仙碱分子被细胞重新摄取有关。秋水仙碱和长春碱摄取动力学的差异可能与其脂溶性差异有关,主要与其与微管蛋白的结合亲和力差异有关。外排动力学的差异此外还可以通过P-糖蛋白参与长春碱的外排来解释,而秋水仙碱的外排不受该泵的影响。事实上,秋水仙碱与微管蛋白的结合意味着大多数细胞内秋水仙碱可能无法被P-糖蛋白接触到。对于像秋水仙碱这样紧密结合细胞内受体的细胞毒性药物,血脑屏障中P-糖蛋白的作用更多的是保护大脑免受这种药物的进入,而不是通过提取来使大脑解毒。